Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study | Zendy

George A. Eby | Zendy; Donald R. Davis | Zendy; William W. Halcomb | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study

Author(s) -

George A. Eby,

Donald R. Davis,

William W. Halcomb

Publication year - 1984

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.25.1.20

Subject(s) - lozenge , placebo , common cold , medicine , irritation , double blind , asymptomatic , zinc , gastroenterology , anesthesia , chemistry , immunology , pathology , alternative medicine , archaeology , organic chemistry , history

As a possible treatment for common colds, we tested zinc gluconate lozenges in a double-blind, placebo-controlled, clinical trial. One 23-mg zinc lozenge or matched placebo was dissolved in the mouth every 2 wakeful h after an initial double dose. After 7 days, 86% of 37 zinc-treated subjects were asymptomatic, compared with only 46% of 28 placebo-treated subjects (P = 0.0005). Side effects or complaints were usually minor and consisted mainly of objectionable taste and mouth irritation. Zinc lozenges shortened the average duration of common colds by about 7 days.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research